SCHEMBL26686484

SCHEMBL26686484

COCCNC(=O)c1cc2c(-c3ccc4[nH]nc(N)c4c3)ccnc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 2/20 0.54
▸ CDK12 Q9NYV4 2/20 0.54
▸ NUDT1 P36639 5/20 0.48
▸ KDM4E B2RXH2 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MAP3K5 Q99683 1/20 0.43
▸ TRPA1 O75762 1/20 0.43
▸ ABL1 P00519 1/20 0.42
▸ BCR P11274 1/20 0.42
▸ JAK2 O60674 1/20 0.41
▸ DYRK1A Q13627 4/20 0.41
▸ WNT1 P04628 2/20 0.41
▸ CLK2 P49760 2/20 0.41
▸ CLK3 P49761 2/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ HASPIN Q8TF76 1/20 0.41
▸ RET P07949 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240633 1.00 CCNK (0.54) CCNKCDK12NUDT1KDM4ESMN1; SMN2
SCHEMBL31240736 0.90 NUDT1 (0.49) CCNKCDK12NUDT1ABL1BCR
SCHEMBL26685908 0.90 NUDT1 (0.49) CCNKCDK12NUDT1ABL1BCR
SCHEMBL26685806 0.88 NUDT1 (0.48) CCNKCDK12NUDT1JAK2DYRK1A
SCHEMBL30633128 0.88 CCNK (0.55) CCNKCDK12NUDT1ABL1BCR
SCHEMBL30633338 0.88 NUDT1 (0.48) CCNKCDK12NUDT1JAK2DYRK1A
SCHEMBL26686576 0.88 CCNK (0.55) CCNKCDK12NUDT1ABL1BCR
SCHEMBL30633157 0.86 CHUK (0.56) CCNKCDK12NUDT1KDM4EABL1
SCHEMBL26685911 0.86 CHUK (0.56) CCNKCDK12NUDT1KDM4EABL1
SCHEMBL31240434 0.86 CHUK (0.57) CCNKCDK12MAP3K5TRPA1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB CCNK 222/4885CDK12 171/4885NUDT1 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback